drugset
drugset / Trial / NCT00095550

Irbesartan/Hydrochlorothiazide (HCTZ) Combination Therapy for Patients With Moderate Hypertension

NCT00095550 ↗

Phase 3 Completed 496 enrolled Bristol-Myers Squibb Sanofi · collab
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this clinical research is to learn if moderate hypertension can be better controlled by initially treating with a combination of drugs (Irbesartan/HCTZ), in patients who are unlikely to achieve blood pressure (B/P) control with only one drug. In addition, the study will also evaluate the safety and tolerability of the drugs.

Timeline

Start
2004-10
Primary completion
2005-06
Completion
2005-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Hydrochlorothiazide Unknown 12.5 mg Oral
Subject Irbesartan Small molecule 150 mg Oral

Indications

hypertensive disorder